Nice | Ticagrelor for the treatment of acute coronary syndrome ACS

4th November 2011 by Louise Hudman

Ticagrelor is a PO drug which inhibits platelet aggregation. In combination with aspirin it is more effective than clopidogrel + aspirin at reducing the endpoint of MI or death from vascular events.

It will be started by secondary care and continued by cardiologists, so we shouldn’t really have to initiate it.

It will be started in patients who’ve had a STEMI where primary percutaneous coronary intervention (PCI) is considered and also in patients with a NSTEMI who have certain other risk factors.

Join

Join to view the rest of this content, as well as access all the benefits of joining NASGP.

Join

Login

Already a member? Login to view this content.

Login

"We’ve worked with the NASGP now for over a decade, and have always been impressed with their commitment to promoting a really productive working relationship between practices and GP locums, with the ultimate aim of making sure patients receive the best care, no matter which GP they see."

Lynda Cox, Practice Cover

Lynda Cox, Practice Cover

See the full list of features within our NASGP membership plans

Membership